1-5 of 5
Wellington Mendes
Close
Sort by
Journal Articles

Long-term follow-up of VIALE-C in patients with untreated AML ineligible for intensive chemotherapy

Clinical Trials & Observations
Andrew H. Wei, Panayiotis Panayiotidis, Pau Montesinos, Kamel Laribi, Vladimir Ivanov, Inho Kim, Jan Novak, Rebecca Champion, Walter Fiedler, Maria Pagoni, Julie Bergeron, Stephen B. Ting, Jing-Zhou Hou, Achilles Anagnostopoulos, Andrew McDonald, Vidhya Murthy, Takahiro Yamauchi, Jianxiang Wang, Qi Jiang, Yan Sun, Brenda Chyla, Wellington Mendes, Courtney D. DiNardo
Journal: Blood
Blood (2022) 140 (25): 2754–2756.
https://doi.org/10.1182/blood.2022016963
Published: 2022
Includes: Supplemental data
Journal Articles

Delays in Time to Deterioration of Health-Related Quality of Life Were Observed in Patients with Acute Myeloid Leukemia Receiving Venetoclax in Combination with Azacitidine or in Combination with Low-Dose Cytarabine

Keith W. Pratz, MD, Panayiotis Panayiotidis, MD, Christian Recher, MD PhD, Xudong Wei, PhD, Brian A Jonas, MD PhD, Pau Montesinos, MD PhD, Vladimir Ivanov, Andre C. Schuh, Courtney D. Dinardo, MDMSc, Jan Novak, Vlatko Pejsa, MD PhD, Don A. Stevens, MD, Su-Peng Yeh, MD, Inho Kim, MD PhD, Mehmet Turgut, MD, Nicola Fracchiolla, Kazuhito Yamamoto, MD PhD, Yishai Ofran, MD, Andrew H Wei, MBBS, PhD, Cat Bui, Katy Benjamin, Rajesh Kamalakar, MS, Jalaja Potluri, MD, Wellington Mendes, Jacob Devine, Walter Fiedler, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 33–35.
https://doi.org/10.1182/blood-2020-133912
Published: 2020
Journal Articles

Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial

Clinical Trials & Observations
Andrew H. Wei, Pau Montesinos, Vladimir Ivanov, Courtney D. DiNardo, Jan Novak, Kamel Laribi, Inho Kim, Don A. Stevens, Walter Fiedler, Maria Pagoni, Olga Samoilova, Yu Hu, Achilles Anagnostopoulos, Julie Bergeron, Jing-Zhou Hou, Vidhya Murthy, Takahiro Yamauchi, Andrew McDonald, Brenda Chyla, Sathej Gopalakrishnan, Qi Jiang, Wellington Mendes, John Hayslip, Panayiotis Panayiotidis
Journal: Blood
Blood (2020) 135 (24): 2137–2145.
https://doi.org/10.1182/blood.2020004856
Published: 2020
Includes: Supplemental data
Journal Articles

The Treatment Cost To Achieve a Complete Cytogenetic Response in Imatinib Resistant Chronic Phase (CP) Chronic Myelogenous Leukemia (CML) Patients: Nilotinib vs. Dasatinib.

Fabio D. Mataveli, MD, Weiwei Feng, PhD, Alessandra Calabró, MBA, Wellington Mendes, MD, Vania Hungria, MD, PhD
Journal: Blood
Blood (2007) 110 (11): 3327.
https://doi.org/10.1182/blood.V110.11.3327.3327
Published: 2007
Journal Articles

Cost-Effectiveness of Imatinib Versus Interferon-α in the Treatment of Patients Newly Diagnosed with Chronic Myeloid Leukemia, under the Brazilian Public Healthcare System Perspective.

Fábio Mataveli, MD, MBA, Alessandra Calabró, MBA, Wellington Mendes, MD, Denizar Vianna, MD,PhD, Pedro Dorlhiac-Llacer, MD,PhD, Ricardo Bigni, MD,PhD, Vania Hungria, MD,PhD
Journal: Blood
Blood (2006) 108 (11): 3314.
https://doi.org/10.1182/blood.V108.11.3314.3314
Published: 2006